Compare Aecom (ACM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Novo Nordisk A/S — how do they compare? Aecom trades at $61.11 (market cap $8.62B), while Novo Nordisk A/S trades at $45.76 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 24.1× Aecom's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ACM | NVO | |
|---|---|---|
Market Cap | $8.62B | $207.85B |
Sector | Industrials | Health |
52-Week High | $134.35 | $63.98 |
52-Week Low | $61.04 | $35.29 |
Enterprise Value | $10.81B | $222.55B |
Dividend Yield | 1.77% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 16.73% to $61.04 amid a Q2 2026 earnings miss, reporting a loss of $0.50 per share versus expectations of $1.46. Despite the recent setback, the company maintains strong analyst support with a 64% buy rating and $88.25 consensus price target. Technical indicators show bearish momentum with the stock trading near key support levels, while fundamentals reveal mixed performance with positive revenue growth but negative ROE and ROA metrics.
The outlook remains cautiously optimistic given the significant analyst upside potential, though investors face near-term volatility from project execution challenges and ongoing securities investigation. Long-term infrastructure demand provides growth tailwinds, but recent earnings volatility and negative profitability ratios warrant careful monitoring of operational improvements.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
